RJA
ALDR

Raymond James & Associates’s Alder Biopharmaceuticals ALDR Stock Holding History

Raymond James & Associates’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,002
Closed -$126K – 3638
2017
Q4 		$126K Buy
11,002
+66
+0.6% +$737 ﹤0.01% 3174
2017
Q3 		$134K Sell
10,936
-406
-4% -$4.23K ﹤0.01% 3144
2017
Q2 		$130K Sell
11,342
-6,847
-38% -$127K ﹤0.01% 3080
2017
Q1 		$378K Buy
18,189
+1,076
+6% +$23.8K ﹤0.01% 2554
2016
Q4 		$356K Buy
17,113
+25
+0.1% +$650 ﹤0.01% 2537
2016
Q3 		$560K Buy
17,088
+2,568
+18% +$78.2K ﹤0.01% 2198
2016
Q2 		$363K Buy
14,520
+2,956
+26% +$80K ﹤0.01% 2293
2016
Q1 		$283K Sell
11,564
-237
-2% -$5.49K ﹤0.01% 2371
2015
Q4 		$390K Buy
11,801
+398
+3% +$13.5K ﹤0.01% 2099
2015
Q3 		$374K Buy
+11,403
New +$485K ﹤0.01% 2051

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Raymond James & Associates's ALDR Position: Q1 2018 in Review

Raymond James & Associates sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 11,002 shares — an estimated $126K sold.

Raymond James & Associates first reported a position in ALDR in Q3 2015 and held it in 10 quarters. The position peaked at $560K in Q3 2016. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Raymond James & Associates reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Raymond James & Associates sold 11,002 Alder Biopharmaceuticals shares in Q1 2018, an estimated $126K.
  • Raymond James & Associates first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 10 quarters.
  • Raymond James & Associates's Alder Biopharmaceuticals position peaked at $560K in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.